• Principles and general themes
• 48 min
  1. Oncolytic viruses: strategies, applications and challenges

  • Dr. Stephen J. Russell
• 44 min
  2. Directed evolution of AAV delivery systems for clinical gene therapy

  • Prof. David Schaffer
• 47 min
  3. Gene transfer strategies: principles, state-of-the-art and the major barriers that need to be overcome 1

  • Prof. Luigi Naldini
• 30 min
  4. Gene transfer strategies: principles, state-of-the-art and the major barriers that need to be overcome 2

  • Prof. Luigi Naldini
• 36 min
  5. Manufacturing viral gene therapy vectors: general approaches and challenges

  • Prof. John T. Gray
• 41 min
  6. The host response: adaptive immune response to viral vector delivery

  • Prof. Roland W. Herzog
• 46 min
  7. Gene therapy and virotherapy in the treatment of cancer

  • Prof. Leonard Seymour
• 66 min
  8. Gene therapy for the muscular dystrophies

  • Prof. Jeff Chamberlain
• Major gene transfer platforms and gene therapy strategies
• 44 min
  9. Gammaretroviral vectors: biology, design and applications

  • Prof. Axel Schambach
• 58 min
  10. Lentiviral vectors: design, biological properties, milestones and current major applications, hazards 1

  • Prof. Luigi Naldini
• 38 min
  11. Lentiviral vectors: design, biological properties, milestones and current major applications, hazards 2

  • Prof. Luigi Naldini
• 50 min
  12. Gene therapy and gene transfer: vector integration preferences and integration site analysis

  • Prof. Frederic Bushman
• 29 min
  13. Surface-mediated targeting of lentiviral vectors

  • Prof. Dr. Christian Buchholz
• 58 min
  14. Gene transfer and gene therapy

  • Dr. David A. Williams
• 35 min
  15. Tracking vector insertion sites to explore the biology of transduced cells in vivo

  • Prof. Dr. Christof Von Kalle
• 22 min
  16. Advances in gene therapy for respiratory diseases 1

  • Prof. John F. Engelhardt
• 41 min
  17. Advances in gene therapy for respiratory diseases 2

  • Prof. John F. Engelhardt
• 37 min
  18. Hematopoietic stem cell gene therapy for the treatment of metachromatic leukodystrophy

  • Dr. Alessandra Biffi
• 59 min
  19. Turning genomic junk into treasure: genetic engineering with the Sleeping Beauty transposon system

  • Dr. Zoltan Ivics
• 56 min
  20. Gene therapy for hemophilia

  • Prof. Katherine High
• New technologies for sequence-specific editing of gene expression
• 57 min
  21. Helper-dependent adenoviral vectors for gene therapy

  • Prof. Nicola Brunetti-Pierri
• 38 min
  22. HSV vectors: approaches to the treatment of chronic pain

  • Prof. Joseph C. Glorioso
• Archived Lectures *These may not cover the latest advances in the field
• 48 min
  23. RNAi for neurological diseases

  • Prof. Beverly L. Davidson
• 52 min
  24. Directed evolution of novel adeno-associated viral vectors for gene therapy

  • Prof. David Schaffer

Printable Handouts

PDF

Navigable Slide Index

1. Introduction
2. Disclosure
3. Oncolytic virotherapy
4. Any virus can be adapted
5. Key considerations in oncolytic virotherapy
6. What can we learn from studies of natural virus pathogenesis?
7. Poliovirus pathogenesis in humans and transgenic mice
8. Oncolytic virus examples
9. Measles pathogenesis
10. Origin of MV-NIS, a safe, trackable oncolytic measles virus
11. Durable complete remission of disseminated cancer after a single MV-NIS infusion
12. Anti-measles antibodies negate the efficacy of intravenous MV-NIS
13. Targeting: Receptor-specific measles viruses displaying cell-targeting ligands
14. Targeting an MHC-peptide complex with a measles virus displaying scTCR
15. Discriminating receptor density on target cells using measles viruses
16. Stealthed, targeted, armed measles virus (MV-STAR)
17. Oncolytic virus examples: Vesicular stomatitis virus
18. Vesicular stomatitis virus
19. First-in-human clinical trial of VSV (VSV-IFNβ) as intratumoral therapy
20. Case details: Tumor lysis after intratumoral VSV-IFNβ
21. Postulated MOA for intratumoral VSV
22. Intravenous VSV-IFNβ-NIS
23. Intravenous VSV-IFNβ-NIS: Higher doses are more effective
24. VSV-IFNβ-NIS canine lymphoma trial
25. Human trial of intravenous VSV-IFNβ-NIS in hematologic malignancies
26. Voyager-V1 is active after a single infusion
27. Postulated MOA for intravenous VSV-IFNβ-NIS in T cell lymphoma
28. Combination therapy with VSV-mIFNβ-NIS + αPD1 + αCTLA4 antibodies
29. VSV-IFNβ-NIS in human subjects: Experience to date
30. Oncolytic virus examples: Picornaviruses
31. Infectious picornavirus RNA
32. Coxsackievirus A21
33. Oncolytic virus examples: Herpesviruses
34. Status of the OV field Q1 2023
35. Boosting the clinical efficacy of T-VEC via combination therapy
36. Combining herpesviruses (HSV+CMV) as an alternative approach for boosting OV efficacy
37. HSV1-IL12 + mCMV are synergistic in a bilateral B16-F10-nectin1 model
38. Taking intratumoral OVs to the next level
39. CMV to convert infected cells into lentiviral vector factories
40. Envisioned strategy to use CMV as an oncolytic vector that also delivers lentiviral CAR-T therapy
41. Conclusions
42. Acknowledgments

Topics Covered

• Measles
• Vesicular stomatitis virus
• Picornavirus
• Herpesvirus
• Coxsackievirus
• Cytomegalovirus
• Modified Measles Virus (MV-NIS)
• T cell lymphoma
• Clinical trials
• Voyager-V1
• Talimogene laherparepvec (T-VEC)

Links

Series:

• Gene Transfer and Gene Therapy

Categories:

• Cancer

Therapeutic Areas:

• Oncology

Talk Citation

Publication History

• Published on September 28, 2023

Financial Disclosures

• Dr. Russell is a cofounder, shareholder and CEO of Vyriad, a company that is developing and commercializing targeted genetic medicines, including oncolytic virus therapies.